Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 8/20 | 0.41 |
| ▸ | JAK1 | P23458 | 8/20 | 0.41 |
| ▸ | WEE1 | P30291 | 2/20 | 0.40 |
| ▸ | INSR | P06213 | 4/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495587 | 0.92 | SYK (0.41) | PAK1JAK2JAK1WEE1JAK3 | |
| SCHEMBL3496243 | 0.90 | PRKCQ (0.49) | PAK1JAK2INSRALKTYK2 | |
| SCHEMBL3495099 | 0.89 | JAK2 (0.45) | PAK1JAK2JAK1INSRALK | |
| SCHEMBL3496551 | 0.88 | PAK1 (0.57) | PAK1JAK2WEE1ALKJAK3 | |
| SCHEMBL3496481 | 0.88 | ULK1 (0.46) | PAK1ALKJAK3 | |
| SCHEMBL3495670 | 0.87 | JAK1 (0.44) | PAK1JAK2JAK1INSRALK | |
| SCHEMBL3493784 | 0.87 | JAK2 (0.45) | PAK1JAK2JAK1INSRALK | |
| SCHEMBL3497098 | 0.86 | PRKCQ (0.46) | PAK1JAK2JAK1INSRALK | |
| SCHEMBL3496877 | 0.84 | JAK2 (0.48) | PAK1JAK2JAK1ALKTYK2 | |
| SCHEMBL3495391 | 0.81 | PRKCQ (0.52) | JAK2JAK1PRKCQCSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | PAK1 105/4885JAK2 268/4885JAK1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.